Combination of interleukin-12 gene therapy, metronomic cyclophosphamide and DNA cancer vaccination directs all arms of the immune system towards tumor eradication

Journal of Controlled Release

Volumn 187, Issue , 2014, Pages 175-182

  Denies, Sofie ^a   Cicchelero, Laetitia ^a   Van Audenhove, Isabel ^b   Sanders, Niek N ^a  

^a GHENT UNIVERSITY   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

Author keywords

Immunotherapy; Interleukin 12; Melanoma; Metronomic chemotherapy; Tyrosinase vaccine

Indexed keywords

CHEMOTHERAPY; CURING; DNA; IMMUNE SYSTEM; MAMMALS; TUMORS; VACCINES;

ANTI-TUMOR IMMUNE; CLINICAL EFFICACY; COMBINATION THERAPY; COMBINATION TREATMENTS; IMMUNOTHERAPY; INTERLEUKIN-12; MELANOMA; REGULATORY T CELLS;

GENE THERAPY;

CANCER VACCINE; CYCLOPHOSPHAMIDE; DNA VACCINE; INTERLEUKIN 12; MONOPHENOL MONOOXYGENASE; ALKYLATING AGENT; CYTOKINE;

ALOPECIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; CANCER GENE THERAPY; CANCER IMMUNIZATION; CANCER SURVIVAL; CELLULAR IMMUNITY; CONTROLLED STUDY; DNA IMMUNIZATION; DRUG EFFICACY; DRUG SAFETY; ELECTROPORATION; HAIR LOSS; HUMORAL IMMUNITY; IMMUNE SYSTEM; IN VITRO STUDY; LETHARGY; LOW DRUG DOSE; LYMPHOCYTE ACTIVATION; MELANOMA B16; METRONOMIC DRUG ADMINISTRATION; MOUSE; MULTIMODALITY CANCER THERAPY; NATURAL KILLER CELL; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR NECROSIS; ANIMAL; BLOOD; GENE THERAPY; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; NEOPLASMS; PATHOLOGY; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; CANCER VACCINES; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; CYTOKINES; GENETIC THERAPY; HUMANS; INTERLEUKIN-12; MICE; MONOPHENOL MONOOXYGENASE; NEOPLASMS; T-LYMPHOCYTES, REGULATORY; TUMOR BURDEN; VACCINES, DNA;

EID: 84902593667     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2014.05.045     Document Type: Article

References (46)

1. K.K. Jain Personalized cancer vaccines Expert. Opin. Biol. Ther. 10 2010 1637 1647
2. F. Belardelli, and M. Ferrantini Cytokines as a link between innate and adaptive antitumor immunity Trends Immunol. 23 2002 201 208 (Pubitemid 34260936)
3. I. Poschke, D. Mougiakakos, and R. Kiessling Camouflage and sabotage: tumor escape from the immune system Cancer Immunol. Immunother. 60 2011 1161 1171
4. G. Trinchieri Recognition of major histocompatibility complex class I antigens by natural killer cells J. Exp. Med. 180 1994 417 421 (Pubitemid 24224118)
5. L. Zamai, C. Ponti, P. Mirandola, G. Gobbi, S. Papa, L. Galeotti, L. Cocco, and M. Vitale NK cells and cancer J. Immunol. 178 2007 4011 4016 (Pubitemid 46492347)
6. C. Asselin-Paturel, N. Lassau, J.M. Guinebretiere, J. Zhang, F. Gay, F. Bex, S. Hallez, J. Leclere, P. Peronneau, F. Mami-Chouaib, and S. Chouaib Transfer of the murine interleukin-12 gene in vivo by a Semliki Forest virus vector induces B16 tumor regression through inhibition of tumor blood vessel formation monitored by Doppler ultrasonography Gene Ther. 6 1999 606 615 (Pubitemid 29192669)
7. C.E. Steding, S.T. Wu, Y. Zhang, M.H. Jeng, B.D. Elzey, and C. Kao The role of interleukin-12 on modulating myeloid-derived suppressor cells, increasing overall survival and reducing metastasis Immunology 133 2011 221 238
8. V.M. Del, E. Bajetta, S. Canova, M.T. Lotze, A. Wesa, G. Parmiani, and A. Anichini Interleukin-12: biological properties and clinical application Clin. Cancer Res. 13 2007 4677 4685 (Pubitemid 47294773)
9. M.L. Lucas, and R. Heller IL-12 gene therapy using an electrically mediated nonviral approach reduces metastatic growth of melanoma DNA Cell Biol. 22 2003 755 763 (Pubitemid 38032998)
10. M. Cemazar, T. Jarm, and G. Sersa Cancer electrogene therapy with interleukin-12 Curr. Gene Ther. 10 2010 300 311
11. I. Mellman, G. Coukos, and G. Dranoff Cancer immunotherapy comes of age Nature 480 2011 480 489
12. L.F. Morris, and A. Ribas Therapeutic cancer vaccines Surg. Oncol. Clin. N. Am. 16 2007 819 831 (ix) (Pubitemid 350101274)
13. F.K. Stevenson, C.H. Ottensmeier, and J. Rice DNA vaccines against cancer come of age Curr. Opin. Immunol. 22 2010 264 270
14. B. Weide, C. Garbe, H.G. Rammensee, and S. Pascolo Plasmid DNA- and messenger RNA-based anti-cancer vaccination Immunol. Lett. 115 2008 33 42 (Pubitemid 350298588)
15. D.A. Grosenbaugh, A.T. Leard, P.J. Bergman, M.K. Klein, K. Meleo, S. Susaneck, P.R. Hess, M.K. Jankowski, P.D. Jones, N.F. Leibman, M.H. Johnson, I.D. Kurzman, and J.D. Wolchok Safety and efficacy of a xenogeneic DNA vaccine encoding for human tyrosinase as adjunctive treatment for oral malignant melanoma in dogs following surgical excision of the primary tumor Am. J. Vet. Res. 72 2011 1631 1638
16. J. Yuan, G. Ku, M. Adamow, Z. Mu, S. Tandon, D. Hannaman, P. Chapman, G. Schwartz, R. Carvajal, K. Panageas, A. Houghton, and J. Wolchok Immunologic responses to xenogeneic tyrosinase DNA vaccine administered by electroporation in patients with malignant melanoma J. Immunol. Ther. Cancer 1 2013 20
17. R. Wesolowski, J. Markowitz, and W. Carson Myeloid derived suppressor cells - a new therapeutic target in the treatment of cancer J. Immunol. Ther. Cancer 1 2013 10
18. H. Pere, C. Tanchot, J. Bayry, M. Terme, J. Taieb, C. Badoual, O. Adotevi, N. Merillon, E. Marcheteau, V.R. Quillien, C. Banissi, A. Carpentier, F. Sandoval, M. Nizard, F. Quintin-Colonna, G. Kroemer, W.H. Fridman, L. Zitvogel, S.P. Oudard, and E. Tartour Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer Oncoimmunology 1 2012 326 333
19. J. Zhao, Y. Cao, Z. Lei, Z. Yang, B. Zhang, and B. Huang Selective depletion of CD4 + CD25 + Foxp3 + regulatory T cells by low-dose cyclophosphamide is explained by reduced intracellular ATP levels Cancer Res. 70 2010 4850 4858
20. I.K. Van, J. Bethuyne, S. Cool, F. Impens, D. Ruano-Gallego, W.O. De, B. Vanloo, T.M. Van, K. Lambein, C. Boucherie, E. Martens, O. Zwaenepoel, G. Hassanzadeh-Ghassabeh, J. Vandekerckhove, K. Gevaert, L.A. Fernandez, N.N. Sanders, and J. Gettemans A nanobody targeting the F-actin capping protein CapG restrains breast cancer metastasis Breast Cancer Res. 15 2013 R116
21. U. Emmenegger, Y. Shaked, S. Man, G. Bocci, I. Spasojevic, G. Francia, A. Kouri, R. Coke, W. Cruz-Munoz, S.M. Ludeman, O.M. Colvin, and R.S. Kerbel Pharmacodynamic and pharmacokinetic study of chronic low-dose metronomic cyclophosphamide therapy in mice Mol. Cancer Ther. 6 2007 2280 2289 (Pubitemid 47294756)
22. + T cells Gene Ther. 14 2007 921 929 (Pubitemid 46865503)
23. M. Othus, B. Barlogie, M.L. Leblanc, and J.J. Crowley Cure models as a useful statistical tool for analyzing survival Clin. Cancer Res. 18 2012 3731 3736
24. C.M. Divino, S.H. Chen, W. Yang, S. Thung, S.T. Brower, and S.L. Woo Anti-tumor immunity induced by interleukin-12 gene therapy in a metastatic model of breast cancer is mediated by natural killer cells Breast Cancer Res. Treat. 60 2000 129 134 (Pubitemid 30307472)
25. + T cells directly induces apoptosis of mouse hepatocellular carcinoma J. Hepatol. 45 2006 662 672 (Pubitemid 44488582)
26. Y. Hamano, H. Sugimoto, M.A. Soubasakos, M. Kieran, B.R. Olsen, J. Lawler, A. Sudhakar, and R. Kalluri Thrombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression Cancer Res. 64 2004 1570 1574 (Pubitemid 38428672)
27. J.C. Becker, R. Houben, D. Schrama, H. Voigt, S. Ugurel, and R.A. Reisfeld Mouse models for melanoma: a personal perspective Exp. Dermatol. 19 2010 157 164
28. M.L. Lucas, L. Heller, D. Coppola, and R. Heller IL-12 plasmid delivery by in vivo electroporation for the successful treatment of established subcutaneous B16.F10 melanoma Mol. Ther. 5 2002 668 675 (Pubitemid 34624563)
29. H. Kim, and J.I. Sin Electroporation driven delivery of both an IL-12 expressing plasmid and cisplatin synergizes to inhibit B16 melanoma tumor growth through an NK cell mediated tumor killing mechanism Hum. Vaccin Immunother. 8 2012 1714 1721
30. I. Airoldi, C.E. Di, C. Cocco, G. Taverniti, T. D'Antuono, E. Ognio, M. Watanabe, D. Ribatti, and V. Pistoia Endogenous IL-12 triggers an antiangiogenic program in melanoma cells Proc. Natl. Acad. Sci. U. S. A. 104 2007 3996 4001 (Pubitemid 47181567)
31. M. Malvicini, M. Rizzo, L. Alaniz, F. Pinero, M. Garcia, C. Atorrasagasti, J.B. Aquino, V. Rozados, O.G. Scharovsky, P. Matar, and G. Mazzolini A novel synergistic combination of cyclophosphamide and gene transfer of interleukin-12 eradicates colorectal carcinoma in mice Clin. Cancer Res. 15 2009 7256 7265
32. B.P. Arulanandam, J.N. Mittler, W.T. Lee, M. O'Toole, and D.W. Metzger Neonatal administration of IL-12 enhances the protective efficacy of antiviral vaccines J. Immunol. 164 2000 3698 3704 (Pubitemid 30169825)
33. T.L. Whiteside, and S. Ferrone For breast cancer prognosis, immunoglobulin kappa chain surfaces to the top Clin. Cancer Res. 18 2012 2417 2419
34. M. Schmidt, B. Hellwig, S. Hammad, A. Othman, M. Lohr, Z. Chen, D. Boehm, S. Gebhard, I. Petry, A. Lebrecht, C. Cadenas, R. Marchan, J.D. Stewart, C. Solbach, L. Holmberg, K. Edlund, H.G. Kultima, A. Rody, A. Berglund, M. Lambe, A. Isaksson, J. Botling, T. Karn, V. Muller, A. Gerhold-Ay, C. Cotarelo, M. Sebastian, R. Kronenwett, H. Bojar, H.A. Lehr, U. Sahin, H. Koelbl, M. Gehrmann, P. Micke, J. Rahnenfuhrer, and J.G. Hengstler A comprehensive analysis of human gene expression profiles identifies stromal immunoglobulin kappa C as a compatible prognostic marker in human solid tumors Clin. Cancer Res. 18 2012 2695 2703
35. T. Mine, Y. Sato, M. Noguchi, T. Sasatomi, R. Gouhara, N. Tsuda, S. Tanaka, H. Shomura, K. Katagiri, T. Rikimaru, S. Shichijo, T. Kamura, T. Hashimoto, K. Shirouzu, A. Yamada, S. Todo, K. Itoh, and H. Yamana Humoral responses to peptides correlate with overall survival in advanced cancer patients vaccinated with peptides based on pre-existing, peptide-specific cellular responses Clin. Cancer Res. 10 2004 929 937 (Pubitemid 38198892)
36. A.E. Gilbert, P. Karagiannis, T. Dodev, A. Koers, K. Lacy, D.H. Josephs, P. Takhar, J.L. Geh, C. Healy, M. Harries, K.M. Acland, S.M. Rudman, R.L. Beavil, P.J. Blower, A.J. Beavil, H.J. Gould, J. Spicer, F.O. Nestle, and S.N. Karagiannis Monitoring the systemic human memory B cell compartment of melanoma patients for anti-tumor IgG antibodies PLoS ONE 6 2011 e19330
37. E.L. Pearce, and H. Shen Generation of CD8 T cell memory is regulated by IL-12 J. Immunol. 179 2007 2074 2081
38. + T cells PLoS Pathog. 6 2010 e1000815
39. F.J. Kohlhapp, A. Zloza, J.A. O'Sullivan, T.V. Moore, A.T. Lacek, M.C. Jagoda, J. McCracken, D.J. Cole, and J.A. Guevara-Patino CD8(+) T cells sabotage their own memory potential through IFN-gamma-dependent modification of the IL-12/IL-15 receptor alpha axis on dendritic cells J. Immunol. 188 2012 3639 3647
40. J.C. Becker, N. Varki, E.B. Brocker, and R.A. Reisfeld Lymphocyte-mediated alopecia in C57BL/6 mice following successful immunotherapy for melanoma J. Investig. Dermatol. 107 1996 627 632 (Pubitemid 26338591)
41. V. Bronte, E. Apolloni, R. Ronca, P. Zamboni, W.W. Overwijk, D.R. Surman, N.P. Restifo, and P. Zanovello Genetic vaccination with "self" tyrosinase-related protein 2 causes melanoma eradication but not vitiligo Cancer Res. 60 2000 253 258 (Pubitemid 30070745)
42. J.G. O'Leary, M. Goodarzi, D.L. Drayton, and U.H. von Andrian T cell- and B cell-independent adaptive immunity mediated by natural killer cells Nat. Immunol. 7 2006 507 516
43. J.C. Sun, S. Madera, N.A. Bezman, J.N. Beilke, M.H. Kaplan, and L.L. Lanier Proinflammatory cytokine signaling required for the generation of natural killer cell memory J. Exp. Med. 209 2012 947 954
44. T. Zhang, J.M. Scott, I. Hwang, and S. Kim Cutting edge: antibody-dependent memory-like NK cells distinguished by FcRgamma deficiency J. Immunol. 190 2013 1402 1406
45. D. Chinnasamy, Z. Yu, S.P. Kerkar, L. Zhang, R.A. Morgan, N.P. Restifo, and S.A. Rosenberg Local delivery of interleukin-12 using T cells targeting VEGF receptor-2 eradicates multiple vascularized tumors in mice Clin. Cancer Res. 18 2012 1672 1683
46. J. Cutrera, D. Dibra, X. Xia, A. Hasan, S. Reed, and S. Li Discovery of a linear peptide for improving tumor targeting of gene products and treatment of distal tumors by IL-12 gene therapy Mol. Ther. 19 2011 1468 1477